已收盤 02-06 16:00:00 美东时间
-0.180
-0.86%
Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:NBTX) with a Buy and raises the price target from $8 to $26.
02-06 22:40
U.S. stock futures were mostly lower this morning, with the S&P 500 futures...
2025-11-11 21:29
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
2025-10-31 20:10
$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial
2025-10-31 15:18
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-10-28 22:14
Nanobiotix announced the completion of transferring sponsorship and operational control of the NANORAY-312 clinical trial for JNJ-1900 (NBTXR3) to Johnson & Johnson. Interim data analysis is expected in 1H2027 after recruitment and requisite events. Nanobiotix will continue to provide updates on its sponsored studies and collaborations. JNJ-1900, a novel oncology product, is activated by radiotherapy and has shown potential in treating solid tumo...
2025-10-24 06:00
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
2025-10-20 20:10
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
2025-10-08 22:39
Nanobiotix Sa ADR ( ($NBTX) ) has released its Q2 earnings. Here is a breakdown...
2025-10-04 11:50
Nanobiotix S.A. press release (OTC:NNBXF): 1H GAAP EPS of -€0.11. Revenue of €26.6M. More on Nanobiotix Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case Nanobiotix S.A. (NBTX)...
2025-10-01 22:07